Bill > HR5160

This bill reauthorizes the Stem Cell Therapeutic and Research Act, specifically extending and updating two key provisions related to cell transplantation and cord blood research. First, the bill increases funding for the C.W. Bill Young Cell Transplantation Program, raising the authorized appropriation from $31,009,000 to $33,009,000 annually for fiscal years 2027 through 2031. This program supports national efforts to coordinate and improve stem cell and bone marrow transplantation. Second, the bill extends the authorization for maintaining a national cord blood inventory from 2026 to 2031. Cord blood, which is collected from the umbilical cord after birth, contains valuable stem cells that can be used in medical treatments for various diseases. By reauthorizing these programs, the bill ensures continued federal support for critical stem cell research and therapeutic initiatives, helping to advance medical treatments and potentially improve patient outcomes in areas like cancer treatment, genetic disorders, and other conditions treatable with stem cell therapies.

Business and Industry

https://www.congress.gov/bill/119th-congress/house-bill/5160/all-info